^
    Back
    Association details:
    Biomarker:BAP1 mutation
    Cancer:Renal Cell Carcinoma
    Drug Class:Glutamate inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    KCRS 2020
    Title:

    Studying BAP1 in Regulating Glucose Dependency in Renal Cancer: Mechanisms and Preclinical Translation

    Excerpt:
    ...Our studies may identify GLUT inhibitors as effective therapies to treat renal cancer patients with BAP1 mutation or deficiency.